95 to 3.74 L/h). However, these differences were not statistically different and could have been due to high variability

in individual Ae24h values (range 0.685–12.0%; CV 81.4%) compared with AUC24h on day 5 (range 197–351 ng · h/mL; CV 19.3%). Drug-Drug Interaction with Methotrexate (Study 2) GLPG0259 and methotrexate plasma concentration–time data are plotted in figure 3, and GLPG0259 and methotrexate pharmacokinetic parameters with summary statistical analyses are presented in table IV. Regarding GLPG0259, co-administration of methotrexate 7.5 mg did not significantly alter the rate and extent of absorption of GLPG0259, with point estimates for Cmax and AUC24h of 102.67% and 102.11%, respectively. Although the t1/2,λz of GLPG0259 could be estimated on one occasion only, there was no modification of the elimination, as shown by the superimposable Tipifarnib in vivo elimination phases with or without methotrexate in figure 3. It must be noted that even if the study was not powered to analyze the influence PLX4032 clinical trial of methotrexate on GLPG0259 pharmacokinetics, using the 90% CI approach, the intervals were narrow and their boundaries fell within the 80–125% buy Dibutyryl-cAMP bioequivalence range for both Cmax and AUC24h (table IV). These results are explained by the low/moderate within-subject variability in GLPG0259 pharmacokinetics (<20%) and suggest that

a sample size of 12 subjects would be sufficient to show bioequivalence between two treatments. Table IV Summary statistics for GLPG0259 and methotrexate pharmacokinetic parameters (n = 6) Fig. 3 Mean (± standard error of the mean) plasma concentrations

of (a) GLPG0259 and (b) methotrexate after administration of each drug alone or in combination to fed healthy subjects (n = 6). The plasma pharmacokinetic parameters of methotrexate observed in this study were in agreement with those reported previously for the methotrexate 7.5 mg dose.[14,15] When methotrexate was co-administered with GLPG0259 50 mg, the rate of absorption of methotrexate was slightly but not statistically significantly decreased, with a point estimate for Cmax of 89.63% (figure 3, table IV). The extent of absorption (AUC∞) and the elimination (t1/2,λz) of methotrexate were not affected by GLPG0259, and their point estimates were 118.22% and 110.64%, respectively. Bioavailability and Food Interaction Studies (Studies 1, 3, and 4) As 4-Aminobutyrate aminotransferase shown in figure 4a, food did not have an impact on the rate and extent of absorption of GLPG0259 given as 100 mg of free-base oral solution, with a Cmax of 31.8 ng/mL (versus 31.0 ng/mL in the fasted state) and an AUC24h of 562 ng · h/mL (versus 572 ng · h/mL in the fasted state) [table V], and corresponding point estimates of 89.67% (90% CI 74.71, 107.61) and 100.42% (90% CI 83.46, 120.83), respectively (table VI). Table V GLPG0259 pharmacokinetic parameters after a single oral dose of GLPG0259 given as various oral formulations to fasted or fed healthy subjects (n = 6 or 12 per formulation) Table VI Table VI.